Citius Oncology, Inc. Increase (Decrease) in Due to Other Related Parties, Current
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Due to Other Related Parties, Current of $2.31 million for the 3-month period ending 2024-12-31, per its 10-Q filed 2025-02-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent · last filed 2025-02-14
- Citius Oncology, Inc. increase (decrease) in due to other related parties, current for the quarter ending 2024-12-31 was $2.31M, a 41.58% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in due to other related parties, current for the quarter ending 2023-12-31 was $3.95M.
- Citius Oncology, Inc. increase (decrease) in due to other related parties, current for fiscal 2024 was $14.27M, a 3.61% decline from fiscal 2023.
- Citius Oncology, Inc. increase (decrease) in due to other related parties, current for fiscal 2023 was $14.81M.
| Period end | Increase (Decrease) in Due to Other Related Parties, Current 3 month | Increase (Decrease) in Due to Other Related Parties, Current 12 month |
|---|---|---|
| 2024-12-31 | $2.31M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $14.27M 10-K · filed 2024-12-27 | |
| 2023-12-31 | $3.95M 10-Q · filed 2025-02-14 | |
| 2023-09-30 | $14.81M 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |